Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISB 1442

Next Previous
Drug Profile

ISB 1442

Alternative Names: CD38 x CD47 biparatopic bispecific antibody; ISB-1442

Latest Information Update: 07 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ichnos Sciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Preclinical Haematological malignancies

Most Recent Events

  • 07 Dec 2024 Adverse events data, pharmacokinetics and pharmacodynamics data from a phase I/II trial for Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 30 Jan 2024 Glenmark and Ichnos enters into an alliance 'Ichnos Glenmark Innovation' to accelerate drug discovery in cancer treatment
  • 09 Dec 2023 Adverse events data, pharmacokinetics and pharmacodynamics data from a phase I/II trial for multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top